Table 1.
Baseline characteristics of the entire cohort
| Variables | Treatment data | P | ||
|---|---|---|---|---|
| All (%) | Group A | Group B | ||
| (N = 26) | (N = 16) | (N = 10) | ||
| Median age, years (range) | 55 (38–69) | 58 (38–69) | 47.5 (40–68) | |
| Gender | 0.422 | |||
| Male | 14 (53.8) | 10 (62.5) | 4 (40) | |
| Female | 12 (46.2) | 6 (37.5) | 6 (60) | |
| Smoking history | 0.420 | |||
| Never smokers | 18 (69.2) | 10 (62.5) | 8 (80) | |
| Former or current smokers | 8 (30.8) | 6 (37.5) | 2 (20) | |
| ECOG PS | 0.138 | |||
| 0–1 | 24 (92.3) | 16 (100) | 8 (80) | |
| ≥ 2 | 2 (7.7) | 0 (0) | 2 (20) | |
| PD-L1 status | 0.474 | |||
| ≥ 50% | 1 (3.8) | 1 (6.3) | 0 (0) | |
| 1–49% | 6 (23.1) | 4 (25) | 2 (20) | |
| Negative | 8 (30.8) | 6 (37.5) | 2 (20) | |
| Unknown | 11 (42.3) | 5 (31.3) | 6 (60) | |
| History of pulmonary resection for lung cancer | 0.538 | |||
| Yes | 3 (11.5) | 1 (6.3) | 2 (20) | |
| No | 23 (88.5) | 15 (93.8) | 8 (80) | |
| Line of ICIs therapy | 0.087 | |||
| First-line | 9 (34.6) | 8 (50) | 1 (10) | |
| > Second-line | 17 (65.4) | 8 (50) | 9 (90) | |
| Best response to ICIs therapy | 0.203 | |||
| PR | 10 (38.5) | 6 (37.5) | 4 (40) | |
| SD | 12 (46.2) | 9 (56.3) | 3 (30) | |
| PD | 4 (15.4) | 1 (6.3) | 3 (30) | |
| Objective response rate, % | 38.5 | 37.5 | 40 | 1.000 |
| Disease control rate, % | 84.6 | 93.8 | 70 | 0.264 |
Group A: combination with chemotherapy; Group B: including monotherapy (n = 5), combination with anti-angiogenesis (n = 3), combination with chemotherapy plus anti-angiogenesis (n = 1), or combination with chemotherapy plus HER2-targeting drugs (n = 1)
ICIs, immune checkpoint inhibitors; ECOG PS, Eastern Cooperative Oncology Group performance status; PR, partial response; SD, stable disease; PD, progression disease